Degenerative disease of nervous system
Methodology & AI Transparency ⓘ
Degenerative disease of nervous system Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as G31.9, Degenerative disease of nervous system falls under Memory & Cognition management, where targeted plasma/CSF biomarker in Degenerative disease of nervous system (G31.9: evaluation when indicated) establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Degenerative disease of nervous system uses ICD-10 G31.9 across Memory & Cognition specialty care.
- 3 Typical cash cost range: Workup highlights for Degenerative disease of nervous system (G31.9): targeted plasma/CSF biomarker in Degenerative disease of nervous system (G31.9: evaluation when indicated).
- 4 Top reported side effects / signs: Longitudinal Degenerative disease of nervous system monitoring tracks TSH & Fasting in Degenerative disease of nervous system (G31.9: ApoB / HbA1c) toward Optimal cardiometabolic neuroprotection (G31.9).
Ask our AI Specialists anything about Degenerative disease of nervous system
What Is Degenerative disease of nervous system?
Designated in federal medical registries as G31.9, Degenerative disease of nervous system falls under Memory & Cognition management, where targeted plasma/CSF biomarker in Degenerative disease of nervous system (G31.9: evaluation when indicated) establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Degenerative disease of nervous system (G31.9) center on neuroinflammatory microglial activation [Degenerative disease of nervous system G31.9]. targeted memory & cognition interventions aim to normalize TSH & Fasting in Degenerative disease of nervous system (G31.9: ApoB / HbA1c).
Common Symptoms & Clinical Signs
- • Presentation of Degenerative disease of nervous system (G31.9): slowed processing speed in Degenerative disease of nervous system (G31.9: compared with prior)
- • Secondary Degenerative disease of nervous system clinical sign: short-term recall difficulty in Degenerative disease of nervous system (G31.9: for recent conversations,)
- • Symptom flares in Degenerative disease of nervous system correlating with TSH & Fasting in Degenerative disease of nervous system (G31.9: ApoB / HbA1c) deviation outside Optimal cardiometabolic neuroprotection (G31.9)
- • Functional memory & cognition impact requiring targeted plasma/CSF biomarker in Degenerative disease of nervous system (G31.9: evaluation when indicated) evaluation (G31.9)
Degenerative disease of nervous system Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G31.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Fasting in Degenerative disease of nervous system (G31.9: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G31.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Degenerative disease of nervous system (G31.9: Score) | >= 26 / 30 (G31.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Degenerative disease of nervous system (G31.9: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Degenerative disease of nervous system
Treatment selection for Degenerative disease of nervous system depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Degenerative disease of nervous system)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pimavanserin safety in adult and older adults patients with neuropsychiatric: What a 595-Participant Study Found The mean. Journal of Alzheimer's disease : JAD • 2025-07-15 • Phase III Randomized Trial | N = 595 | 93/100 | PMID 40518812 ↗ |
| Can This Approach Help? Inside the Latest Research on Brexpiprazole's impacts on patients and caregivers in agitation in Alzheimer's At Week 10, the differences of brexpiprazole 1 and 2 mg versus placebo for NPI total score were -1.2 (p = 0.5891) and -8.4 (p < 0.0001), and those for NPI-Distress total score were -1.1 (p = 0.2292) and -3.9 (p < 0.0001),... Alzheimer's & dementia : the journal of the Alzheimer's Association • 2025-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40717666 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety Profile of Pimavanserin Therapy in older adults Patients with Pimavanserin was well tolerated and not associated with motor or cognitive impairment. Journal of Alzheimer's disease : JAD • 2024-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38427485 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of pimavanserin in patients with Lewy body Psychosis relapse risk was significantly lower with pimavanserin vs. BMC neurology • 2025-11-24 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 41286676 ↗ |
| Can This Approach Help? Inside the Latest Research on Exploration of baseline and early changes in neurocognitive characteristics as These exploratory results warrant further scrutiny, but demonstrate that quick and non-invasive behavioral tests may have substantial clinical value in predicting antidepressant treatment response. Psychological medicine • 2022-10-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 33213541 ↗ |
Degenerative disease of nervous system Patient Community & “People Like Me” Threads
Filter Degenerative disease of nervous system community threads and patient logs by age, biological sex, dosage, and treatment duration.